Reuters logo
9 个月前
BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment
2016年11月22日 / 晚上8点27分 / 9 个月前

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

Nov 22 (Reuters) - Bristol-Myers Squibb Co :

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin

* Approval allows for expanded marketing of Opdivo in relapsed or refractory CHL in all 28 member states of EU Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below